psilocybin has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bird, C; Carter, B; Day, C; Jafari, H; Knight, G; Mantingh, T; Modlin, NL; Reinholdt, F; Rucker, J; Young, A | 1 |
| Hassan, F; Khan, FI; Lai, D | 1 |
| Al-Imam, A; Michalak, M; Motyka, MA; Witulska, Z; Younus, M | 1 |
| Alexander, L; Baker, A; Brennan, C; Burke, L; Crockett, MT; Haran, M; Kelly, JR; O'Keane, V | 1 |
1 trial(s) available for psilocybin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial.
Topics: COVID-19; Depressive Disorder, Major; Feasibility Studies; Humans; Psilocybin; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2021 |
3 other study(ies) available for psilocybin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Topics: Agaricales; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Interleukin-6; Psilocybin; Receptors, Interleukin-6; SARS-CoV-2; Virus Replication | 2021 |
Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland.
Topics: Cannabis; COVID-19; Hallucinogens; Humans; Lysergic Acid Diethylamide; Pandemics; Poland; Psilocybin | 2022 |
Psychedelic science in post-COVID-19 psychiatry.
Topics: COVID-19; Hallucinogens; Humans; Psilocybin; Psychiatry; SARS-CoV-2 | 2021 |